What is Drugs Made In America Acquisition Corp. Rights (DMAAR)?

Drugs Made In America Acquisition Corp. Rights (DMAAR) is a stock in the Financial Services sector, Shell Companies industry. View full analysis on Stocks360.

What is the current price of DMAAR?

The current price of DMAAR is $0.09. Prices are updated in real time on Stocks360.

What is DMAAR's price-to-earnings (PE) ratio?

DMAAR's trailing twelve-month PE ratio is 55.48, based on current price and earnings per share data available on Stocks360.

What is DMAAR's market capitalization?

DMAAR's market capitalization is $220,818,476.00, placing it in the small-cap tier.

Drugs Made In America Acquisition Corp. Rights (DMAAR)

Stock analysis · NASDAQ · Financial Services · Shell Companies

$0.09

Market Cap

$220.82M

PE (TTM)

55.48

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

3.92

Day Range

$0.09 – $0.11

52-wk Range

$0.04 – $0.21

Avg Volume

N/A

Volume

154.08

Drugs Made In America Acquisition Corp. Rights (DMAAR) is a publicly traded company in the Financial Services sector. Latest price: $0.09. Market cap $220.82M. Trailing PE 55.48. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $0.17 2026-10-30 · $0.09 (-47.85%)

Proprietary Signals

Signal snapshot temporarily unavailable.

About Drugs Made In America Acquisition Corp. Rights

Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC), established with the primary objective of identifying and acquiring one or more active businesses or their assets. The company plans to achieve these acquisitions through various transactional structures, including mergers, exchanges of equity shares, direct asset purchases, stock acquisitions, or broader corporate reorganizations.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	55.48×
P/S (TTM)	0.00×
P/B	1.59×
P/FCF (TTM)	-818.17×
EV / EBITDA	-100.75×
EV / Sales	0.00×
Earnings Yield	2.79%
Free Cash Flow Yield	-0.12%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$265.31M
Net Income (TTM)	$7.36M
Free Cash Flow (TTM)	-$323.13K
Net Debt	$929.72K
Working Capital	-$2.88M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	2.92%
Return on Invested Capital	-1.82%